The Form 4 filing was filed on October 29, 2026, for trades made October 27–28. Form 4 is a report of insider stock trades. It lists Julie Rubinstein as Adaptive Biotechnologies' president and chief operating officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-27 |
| Date of Latest Transaction | 2026-10-28 |
| Buy/Sell | sell |
| Transaction Count | 4 |
| Shares Transacted | 23,762 |
| Price | $27.87 |
| Total Transaction Value | $662,221.57 |
| Insider | |
| Ticker Symbol | ADPT |
| Company | Adaptive Biotechnologies Corp |
| Insider Name | RUBINSTEIN JULIE |
| Insider Title | President and COO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 377,802 |
| Position Size Change | 5.92% |
| Filing | |
| Filing Date | 2026-10-29 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of Adaptive Biotechnologies (ADPT) shares. All four transactions are marked with code S, which identifies a sale in the filing.
What was the average price of the transaction?
The average price was $27.87 per share, rounded to the nearest cent. That average covers the four sales. Prices for each sale are not available here.
How did this transaction affect the insider's holdings?
The sales reduced Julie Rubinstein's reported holdings by 23,762 shares, leaving 377,802 shares afterward. She sold 5.92% of the shares she was reported to own before the sales.
What's the total transaction value?
The four sales had a total value of $662,221.57. That amount covers all 23,762 shares sold across the four transactions.
Are there any special circumstances around this transaction?
The transaction information includes a reference to a Rule 10b5-1 trading plan. Such plans set trading instructions in advance. A plan reference can apply to a whole filing without showing which trades it covers.
Footnote text and plan terms are not available here, so it is unclear whether all four sales were covered. The plan's start date and trading schedule are also unknown.
For research purposes only; not investment advice.